INC's backers line up for a big Wall Street payday

The deep-pocketed outfits that helped take INC Research ($INCR) public last year are angling to cash in on the CRO's resulting success on the market, flipping shares in a secondary offering. A group of shareholders including Avista Capital Partners, Teachers' Private Capital and some current and former employees of INC have put up 8 million shares in an offering expected to close next week. At INC's current share price, they stand to gross more than $360 million. The CRO itself will not see any proceeds from the stock sale. Release

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.